GALT - ガレクチン・セラピュ―ティクス （Galectin Therapeutics Inc.） ガレクチン・セラピュ―ティクスGALTのチャート
GALTの企業情報
| symbol | GALT |
|---|---|
| 会社名 | Galectin Therapeutics Inc （ガレクチン・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ガレクチン・セラピューティクス（Galectin Therapeutics Inc.）（旧名：プロ・ファーマシューティカル（Pro-Pharmaceuticals Inc.））は開発段階の会社。同社はガレクチン（Galectin）を標的とする治療薬の発見・開発に従事する。同社は多糖ポリマーを用いた抗癌治療法の開発に集中する。平成21年12月31日現在、同社の製品は前臨床および臨床試験を含み、開発中にある。平成21年12月31日現在、同社は、「Avastin」など生物製剤と「5-FU」など化学療法と併用できる一連の化合物を開発している。平成21年12月31日現在、「DAVANAT」は第I相および第II相試験で約100人のがん患者に投与されている。平成21年12月31日現在、同社は肝臓と腎臓の線維症など他の重篤な疾患を治療する他の治療用化合物を開発している。これらの製品候補は、すべてが開発の前臨床段階にある。 ガレクチン・セラピュ―ティクスは、米国の医薬品研究開発会社。肝線維性疾患とがんの治療法を開発する。同社の薬剤候補は、生物学的および病理学的機能の主要な役割を持つガレクチン・タンパク質を標的とする方法に基づいている。開発中の薬剤「GR-MD-02」は、免疫システム調節剤を複数組み合わせ、肝線維症やがん治療に使用される。本社はジョ―ジア州。 Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin (formerly known as GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of combination immunotherapy for advanced melanoma and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. |
| 本社所在地 | 4960 Peachtree Industrial Blvd. Suite 240 Norcross GA 30071 USA |
| 代表者氏名 | Richard E. Uihlein リチャード・E・ウイ |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 678-620-3186 |
| 設立年月日 | 36708 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 7人 |
| url | www.galectintherapeutics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/galt |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -14.72400 |
| 終値（lastsale） | 5.16 |
| 時価総額（marketcap） | 211115491.8 |
| 時価総額 | 時価総額（百万ドル） 202.11440 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 200.56940 |
| 当期純利益 | 当期純利益（百万ドル） -16.10000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Galectin Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders decreased 14% to $8.7M. Lower net loss reflects Research and development decrease of 62% to $2.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.29 to -$0.23. |
GALTのテクニカル分析
GALTのニュース
HOLO, APCX and ENSV among mid-day movers 2023/02/07 18:19:03 Seeking Alpha
Gainers: Kiora Pharmaceuticals KPRX +39%.Celyad Oncology CYAD +35%.Oak Street Health OSH +30%.Zhihu (ZH) +27%.Berkshire Grey (BGRY) +27%.Galectin Therapeutics (GALT) +19%.Golden…
Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal 2023/01/24 13:00:00 GlobeNewswire
Study to improve histology interpretation of cirrhotic liver biopsies highlights limitations of current histology techniques and re-emphasizes the clinical relevance and regulatory potential of esophago-gastric endoscopies when evaluating candidate therapies for liver cirrhosis. Study to improve histology interpretation of cirrhotic liver biopsies highlights limitations of current histology techniques and re-emphasizes the clinical relevance and regulatory potential of esophago-gastric endoscopies when evaluating candidate therapies for liver cirrhosis.
Galectin Therapeutics: In For A Long 2-Year Wait (NASDAQ:GALT) 2023/01/03 15:29:18 Seeking Alpha
Galectin Therapeutics is all-in on the results of one clinical trial coming in 2024. Click here to read my analysis of GALT stock.
Galectin Therapeutics (GALT) Investor Presentation - Slideshow (NASDAQ:GALT) 2022/11/22 16:42:05 Seeking Alpha
The following slide deck was published by Galectin Therapeutics Inc.
Galectin Therapeutics GAAP EPS of -$0.14 2022/11/14 13:52:46 Seeking Alpha
Galectin Therapeutics press release (GALT): Q3 GAAP EPS of -$0.14.The company believes it has sufficient cash of $15.8M, including availability under its $60 million line of credit,…
Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal 2023/01/24 13:00:00 GlobeNewswire
Study to improve histology interpretation of cirrhotic liver biopsies highlights limitations of current histology techniques and re-emphasizes the clinical relevance and regulatory potential of esophago-gastric endoscopies when evaluating candidate therapies for liver cirrhosis. Study to improve histology interpretation of cirrhotic liver biopsies highlights limitations of current histology techniques and re-emphasizes the clinical relevance and regulatory potential of esophago-gastric endoscopies when evaluating candidate therapies for liver cirrhosis.
Galectin Therapeutics: In For A Long 2-Year Wait (NASDAQ:GALT) 2023/01/03 15:29:18 Seeking Alpha
Galectin Therapeutics is all-in on the results of one clinical trial coming in 2024. Click here to read my analysis of GALT stock.
Galectin Therapeutics (GALT) Investor Presentation - Slideshow (NASDAQ:GALT) 2022/11/22 16:42:05 Seeking Alpha
The following slide deck was published by Galectin Therapeutics Inc.
Galectin Therapeutics GAAP EPS of -$0.14 2022/11/14 13:52:46 Seeking Alpha
Galectin Therapeutics press release (GALT): Q3 GAAP EPS of -$0.14.The company believes it has sufficient cash of $15.8M, including availability under its $60 million line of credit,…
Galectin Therapeutics Inc.: Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update 2022/11/14 13:04:00 Finanz Nachrichten
NORCROSS, Ga., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results a…
Galectin rises as FDA approves to begin human trial of combination immunotherapy in head and neck cancer 2022/10/12 13:05:27 Seeking Alpha
Galectin Therapeutics (GALT) said on Wednesday it had filed an investigational New Drug application with the U.S
Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022 2022/09/08 12:00:00 GlobeNewswire
NORCROSS, Ga., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 24th Annual Global Investment Conference being held on September 12-14, 2022. The Wainwright Conference brings together thought leaders and practitioners from numerous fields to participate in presentations, one-on-one investor meetings, and networking opportunities with other attendees.
Galectin Therapeutics GAAP EPS of -$0.16 2022/08/15 12:42:20 Seeking Alpha
Galectin Therapeutics press release (GALT): Q2 GAAP EPS of -$0.16.As of June 30, 2022, the Company had $24.2M of cash and cash equivalents
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update 2022/08/15 12:00:00 GlobeNewswire
NORCROSS, Ga., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2022. These results are included in the Company''s Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov .
This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday 2022/07/29 09:55:52 Benzinga
Gainers Athersys, Inc. (NASDAQ: ATHX ) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11, 2022. SKYX Platforms Corp. (NASDAQ: SKYX ) gained 68.6% to settle at $7.03. Benchmark initiated coverage on SKYX Platforms with a Buy rating and announced a price target of $15. ECB Bancorp, Inc. (NASDAQ: ECBK ) jumped 40.9% to close at $14.09. Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS ) climbed 37.1% to close at $1.92. Q&K International Group Limited (NASDAQ: QK ) gained 32.6% to close at $1.87. JAKKS Pacific, Inc. (NASDAQ: JAKK ) shares surged 31.5% to close at $22.46 after the company reported better-than-expected Q2 results. Better Therapeutics, Inc. (NASDAQ: BTTX ) surged 30.9% to close at $1.99 after the company completed its clinical trial for BT-001, an investigational prescription digital therapeutic that is designed to use nCBT to treat type 2 diabetes. Sunrun Inc. (NASDAQ: RUN ) surged 30% to settle at $30.92 alongside Sunnova Energy International after the company reported strong top-line financial results and reaffirmed guidance.